MX2017003063A - Prueba de diagnostico basada en fragmento de rgma. - Google Patents

Prueba de diagnostico basada en fragmento de rgma.

Info

Publication number
MX2017003063A
MX2017003063A MX2017003063A MX2017003063A MX2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A
Authority
MX
Mexico
Prior art keywords
diagnostic assay
based diagnostic
fragment based
rgma fragment
rgma
Prior art date
Application number
MX2017003063A
Other languages
English (en)
Inventor
Barghorn Stefan
Striebinger Andreas
Schmidt Martin
Klaus MÜLLER Bernhard
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2017003063A publication Critical patent/MX2017003063A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)

Abstract

Se proveen pruebas de diagnóstico y métodos para utilizar las pruebas de diagnóstico para detectar y cuantificar fragmentos de RGMa en una muestra. Los métodos se pueden utilizar en la detección de los fragmentos de RGMa para monitorear el tratamiento con fármaco y la efectividad del tratamiento con fármaco en enfermedades neurodegenerativas.
MX2017003063A 2014-09-10 2015-09-09 Prueba de diagnostico basada en fragmento de rgma. MX2017003063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048745P 2014-09-10 2014-09-10
PCT/EP2015/070603 WO2016038084A1 (en) 2014-09-10 2015-09-09 Rgma fragment based diagnostic assay

Publications (1)

Publication Number Publication Date
MX2017003063A true MX2017003063A (es) 2017-06-14

Family

ID=54064367

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003063A MX2017003063A (es) 2014-09-10 2015-09-09 Prueba de diagnostico basada en fragmento de rgma.
MX2021009528A MX2021009528A (es) 2014-09-10 2017-03-08 Prueba de diagnostico basada en fragmento de rgma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009528A MX2021009528A (es) 2014-09-10 2017-03-08 Prueba de diagnostico basada en fragmento de rgma.

Country Status (10)

Country Link
US (3) US20160069907A1 (es)
EP (1) EP3191847A1 (es)
JP (1) JP6879905B2 (es)
CN (2) CN113267630A (es)
AU (2) AU2015314240A1 (es)
BR (1) BR112017004883A2 (es)
CA (1) CA2956814A1 (es)
MX (2) MX2017003063A (es)
TW (2) TW201617612A (es)
WO (1) WO2016038084A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2780069C (en) * 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
CA3112511A1 (en) 2018-07-19 2020-01-23 The University Of Tokyo Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham
WO2021145432A1 (ja) * 2020-01-15 2021-07-22 国立大学法人大阪大学 糖尿病性自律神経障害の予防又は治療剤
CN112402554B (zh) * 2020-10-26 2022-03-01 中国中医科学院广安门医院 一种治疗脑白质病的中药组合物及其应用
EP4374300A1 (en) * 2021-07-23 2024-05-29 Cedars-Sinai Medical Center Methods and systems for early detection of ocular and/or neurological conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1095278T3 (da) * 1998-07-03 2006-04-18 Innogenetics Nv Differentialdiagnose af neurodegeneration
ES2390425T3 (es) * 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
US9334323B2 (en) * 2009-12-09 2016-05-10 Mitsubishi Tanabe Pharma Corporation Method of reducing recurrence of multiple sclerosis symptoms in a mammal by administering an anti-repulsive guidance molecule neutralizing antibody
CN103298834A (zh) * 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US9125894B2 (en) * 2010-10-06 2015-09-08 Massachusetts Eye & Ear Infirmary Methods for promoting reinnervation of auditory hair cells
CA2839777C (en) * 2011-06-22 2021-10-19 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
MY194587A (en) * 2012-01-27 2022-12-05 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration

Also Published As

Publication number Publication date
US20220018855A1 (en) 2022-01-20
JP2017526930A (ja) 2017-09-14
US20200241012A1 (en) 2020-07-30
AU2022200160A1 (en) 2022-02-10
CN107076757A (zh) 2017-08-18
TW201617612A (zh) 2016-05-16
JP6879905B2 (ja) 2021-06-02
EP3191847A1 (en) 2017-07-19
CN113267630A (zh) 2021-08-17
US20160069907A1 (en) 2016-03-10
BR112017004883A2 (pt) 2017-12-05
AU2015314240A1 (en) 2017-02-09
MX2021009528A (es) 2021-09-08
WO2016038084A1 (en) 2016-03-17
CA2956814A1 (en) 2016-03-17
TW202119030A (zh) 2021-05-16

Similar Documents

Publication Publication Date Title
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
HK1257999A1 (zh) 用於臨床應用的分析物收集、提取、濃縮和檢測的方法和裝置
CL2017003069A1 (es) Métodos para diagnosticar y tratar el cáncer.
GB2552267B (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
PL3482209T3 (pl) Oznaczenie do wykrywania alfa-synukleiny i sposób diagnozowania alfa-synukleinopatii
SG10201408391RA (en) Means and methods for multimodality analysis and processing ofdrilling mud
EP3186397C0 (en) USE OF BIOMARKERS OF CIRCULATING CELLS IN THE BLOOD FOR THE DETECTION AND DIAGNOSIS OF DISEASES, AND THEIR ISOLATION PROCESSES
PH12017501967A1 (en) Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof
EP3209998A4 (en) Method and system for detection of disease agents in blood
EP3171161A4 (en) Biological substance quantitative determination method, image processing device, pathological diagnosis support system, and program
FR3029288B1 (fr) Procede de detection et de caracterisation par ultrasons de defauts dans un materiau heterogene
IL265712B (en) A method for identifying active forms of an analyte and determining the ability of substances to bind with active sites of an analyte
EP3200118A4 (en) Sample traceability device and method for medical research and/or diagnosis
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
HK1214649A1 (zh) 體外診斷分析方法和系統
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
BR112016028838A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
WO2015042326A3 (en) Methods for detection and treatment of neurodegenerative diseases
SG11201509866TA (en) Protease-responsive peptide biosensors and methods for analyte detection
EP3207374A4 (en) Method and system for determining the concentration of an analyte in a fluid sample
IN2014KN00742A (es)
EP3206032A4 (en) Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure
GB2530521B (en) Mass spectral analysis of patient samples for the detection of the human chorionic gonadotropin
PL3230910T3 (pl) Sposób zarządzania protokołami używanymi przez urządzenia do analizy diagnostycznej i klinicznej oraz wynikami uzyskanymi przez te urządzenia